Sunday, February 27, 2011

Clinical Experience with RNAi Therapeutics Suggests Class to be Remarkably Safe

One of the biggest concerns in developing an entirely new class of drugs is whether they will be well tolerated. At the height of the TLR scare, it almost seemed that just looking at an siRNA would cause you anaphylactic shock. Nevertheless, after several hundreds of patients have been dosed with probably around 1000 siRNA administrations for diseases affecting the eye, lung, skin, blood cells, liver, solid tumors, and kidney, RNAi Therapeutics have shown a very promising safety profile.

When RNAi Therapeutics candidates have been abandoned, it was mostly not because of safety issues, but for factors such as lack of efficacy, doubts about the mechanism of action of observed therapeutic effects, or changes in the commercial attractiveness of compounds (e.g. wet AMD candidates by Allergan/Merck and Opko). In one case, Tekmira’s ApoB SNALP for hypercholesterolemia, the decision to voluntarily abandon this first-generation ApoB candidate after one patient experienced mild flu-like symptoms, may well have had to do with the fact that much more potent LNPs had already been developed by then and there was thus no point to tempt fate and further dose escalate.

It is not surprising that side-effects related to the innate immune stimulatory potential of nucleic acids were the most frequently cited safety issue in clinical trials. In the case of nanoparticles, complement activation seems to be another area where attention needs to be paid. However, even when formulated with lipids, the currently most potent systemic delivery agents but which are known for their potential to amplify immune responses, patient lives have not been needlessly put at risk and the potencies of both Silence’s cationic lipoplexes and Tekmira’s (neutral) LNPs, especially in light of the significantly improved potencies of 2nd generation LNPs, may be well within the therapeutic windows for a number of indications.

The most demanding test for the safety of RNAi Therapeutics are the ongoing cancer trials where the ability to dose escalate is the name of the game. Here, all 4 nanoparticle-formulated candidates by Calando, Silence, and Alnylam, seem to be still dose-escalating after having reached dosages of between 0.1 and 1.25mg/kg, dosages where anti-cancer efficacies may be expected based on animal models.

With this type of record, RNAi Therapeutics does not have to hide behind the more established classes of drugs. Even protein-based therapeutics which are highly sought after by Big Pharma and investors these days (well, all is relative) have to deal with a number of immune-related issues, both direct responses of the immune system to their introduction (anaphylaxis, antibody formation) as well as target-based toxicities as most of these drugs work by suppressing the immune system. And similar to protein-based therapeutics, and maybe even more so because they are likely to resemble each other more than protein-based therapeutics resemble each other, with experience the rate of attrition of RNAi Therapeutics due to safety should only decrease over time.

Monday, February 21, 2011

RNAi Therapeutics is Dead, Long Live RNAi Therapeutics

You have all seen the obituaries on RNAi Therapeutics. Following the terminations of in-house RNAi Therapeutics efforts by Roche, Pfizer, and Novartis (oh wait, Novartis actually hasn’t stopped developing RNAi Therapeutics, but with 31 targets has more than enough on its plate- minor detail), major news outlets have finally pronounced: RNAi Therapeutics is Dead!

Meanwhile, in the 3-4 years since Roche made its famous commitment, the field has made major progress in reaching the market with Tekmira’s liposomal delivery technology rapidly generating a wealth of important clinical data and showing unprecedented efficacy in the most challenging of animal models for Ebola, Silence Therapeutics’ lipoplex delivery technology pleasantly surprising in terms of its safety and first signs of efficacy, a Chinese group reporting success with RNAi Cosmetics in Wo-Man, and Rosetta Genomics having brought to market a microRNA Diagnostic for Cancer of Unknown Primary that, under normal circumstances, that is proper quality control and marketing, should be a commercial success story. Not far behind, RXi Pharmaceuticals is reporting impressive data for their self-delivering rxRNAs in dermal applications.

By any rational standard of scientific progress, this is more than satisfactory, yet investors and the industry itself it seems have become infected by the Big Pharma RNAi Therapeutics mood swings. Actually, Big Pharma should be in the best position to sweep up RNAi assets as pure-play companies experience financial difficulties. However, it seems that it took less guts for Merck to buy Sirna Therapeutics for more than a Billion US dollars than for Big Pharma today to spend about 10 times less to acquire the two companies that have developed the clinically most advanced systemic RNAi delivery technologies: Tekmira and Silence.

Unfortunately, for RNAi Therapeutics to be able to maintain that pace of progress, it depends on (financial) supporters with deep pockets or, ironically, a spark that will ignite another round of RNAi Therapeutics exuberance. Steady scientific progress superimposed by stone-age fear and greed.

Monday, February 14, 2011

Clinical Trial Update for Solid Cancer Candidate Atu-027 Highly Encouraging

After I tried to focus attention on the Silence Therapeutics presentation this afternoon at the BIO CEO & Investor Conference, as soon as I had published my earlier blog I half regretted my decision to do so because more often than not positive news does not materialize when you expect it. This blog in particular is littered with such speculations. Fortunately, this time was different as Silence Therapeutics was able to present some really neat data from the ongoing phase I study with Atu-027 in the treatment of advanced solid cancer.

To date, at least 20 patients have received at least one Atu027 siRNA-lipoplex infusion. While the dose escalation is being conducted in a very cautious manner, i.e. slowly, dosages are now approaching levels of around 0.1mg/kg where therapeutic efficacy may be expected based on pre-clinical non-human primate data. Importantly, after 157 infusions administered, the drug seems to be very well tolerated. The only notable safety concern may be the complement activation likely related to the positive charge of Silence’s lipoplex formulation and that the Company characterized to be ‘limited’ and ‘transient’ in nature. This would be consistent with the fact that no dose limiting toxicity was reported,

There was also anecdotal evidence for anti-tumor efficacy of Atu-027. 5 out of 20 patients experienced stable disease during the 3 month study period with one patient in the sixth cohort (7th dose cohort now dosing) said to exhibit ‘remarkable shrinkage of target and non-target lesions’. There was also a mention of a reduction in lung metastases which could be clinically very meaningful for certain cancers (slide 16). Unfortunately, since this presentation was not webcast live, it is currently difficult for me to figure out the context in which this comment was made.

In sum, from today on, Atu-027 has to be considered one of the foremost RNAi clinical candidates and I look forward to data from the higher dose groups at ASCO. Congrats to the company for having come this far.


Silence Therapeutics to Present Blitz-Update on Atu-027

2011 promises to be a year of rich clinical data flow for RNAi Therapeutics. Results from clinical trials of ALN-VSP02, ALN-TTR01 (both Alnylam), Atu-027 (Silence Therapeutics), and TKM-PLK1 (Tekmira) in particular will be important in shaping the perception of RNAi Therapeutics as an investable drug modality. Following disappointment that Silence Therapeutics was not able to receive an attractive offer following the 'approach', the Company’s announcement this morning that it will provide an update, today at the Annual BIO CEO & Investor Conference, on the phase I trial of Atu-027 for solid cancers, fosters speculation that Silence Therapeutics rejected any bid as undervaluing it because of impending positive trial data and that the better game plan may be to raise capital at elevated prices following positive market reception of the trial data. Clearly, at this point Silence’s future depends to a large degree on Atu027 and the stakes are high.

This is an opportunity for me to urge the pure-play companies to treat retail investors fairly in upcoming financings. Believe it or not, with perhaps the exception of Alnylam, it is retail investors that keep these micro-cap companies alive. Financings of the type that Marina Biotech transacted last week are simply not acceptable: the underwriter and solicited large investors get hefty fees, discounts, and warrants which means that shares will be flipped for a quick profit and dumped onto retail investors which do not get the opportunity to participate on equal terms. In the end, these companies will have squandered the goodwill of their most important constituency as the deals will be perceived as a mutual back-scratching exercise to keep the biotech gravy train going while non-privileged investors lose their investments.

Despite its wide-spread practice, this does not have to be so. For example, in a recent financing by gene therapy company Oxford Biomedica, existing shareholders were given the opportunity to participate in the follow-on offering at the same (very steep) discount as the institutions. To be clear, this deal is still to be considered unfair in that the option to participate still did not allow retail investors to avoid substantial dilution while larger shareholders were given this opportunity and even could increase their stakes at the much reduced prices, on top of the obvious insider trading the week before the financing (but that’s a more general problem, I guess). So to the Tekmira’s, RXi’s and Rosetta’s of the world: if you have to issue shares, please consider your most loyal constituency and treat them fairly.

Early January update on ALN-VSP02

Since I would like to shift the focus of this blog towards the clinical developments in RNAi Therapeutics, a quick re-cap of the data presented by Alnylam a month ago which showed that the LNP-delivered ALN-VP02 achieved therapeutically relevant tissue levels and promoted RNAi-mediated target cleavage in the liver of cancer patients. This is similar to data published in Nature a year ago by Calando with their RNAi compound for solid cancer.

Certainly, the 5’ RACE assay used to determine the RNAi-mediated mechanism is (still) a non-quantitative technology and as such can only tell whether RNAi has occurred or not. However, in practice, this assay is not without its challenges even under standardized tissue culture conditions, so the fact that cleavage could be detected in a clinical setting where sampling issues were especially challenging is an important finding.

The other important piece of new data presented was on the drug accumulation in the liver where about half of the reported values well exceeded the 1ng/mg threshold that Alnylam reported to have 50% Factor VII knockdown efficacy by a log or so (Landesman et al. 2010). Although the dose responsiveness of siRNA accumulation in the liver was a bit shaky, possibly due to sampling challenges, the data also suggests that LNP delivery efficiency to rat and human liver may not differ by too much. It has to be said, however, that ALN-VSP02 is a first gen LNP formulation whereas the 1ng/mg threshold was established with a 2nd gen formulation. Moreover, the 50% threshold is always target gene specific and will differ between Factor VII and the ALN-VSP02-related VEGF.

In sum, the data supports that ALN-VSP02 may have a therapeutically meaningful impact in a subset of patients should maximally tolerated dosages of 1.25mg/kg or above be achieved and the genetics play out as hoped. We should not have to wait much longer for more clarity on the efficacy of ALN-VSP02 given that Alnylam has collected many more biopsies and should have conducted additional types of assays (e.g. RNA knockdown; mitotic spreads for spindle abnormalities expected from KSP knockdown etc) than were reported on.

Friday, February 4, 2011

Big Pharma and RNAi Therapeutics: In-house Platform Development is ‘Out’, External Product-specific Deals are ‘In’

As if to add insult to injury, a few month after Roche exiting RNAi Therapeutics, plans emerged that Pfizer is about to shut down internal oligonucleotide therapeutics development efforts. This is depressing news for sure to me, and I would assume the wider RNAi Therapeutics community. But then again maybe not that surprising, and it would shock me no more to see Last-Man-Standing Merck shut down as well if the Tuschl trial goes against them.

Just as Big Pharma jumped onto the RNAi Therapeutics bandwagon 3-5 years ago, seemingly believing that all you need to do is to inject an siRNA into the blood and all those multi-billion dollar patent expiration woes will go away, the Big Pharma herd is now running for the exits. If you study this quarter’s financial results by Pfizer and Merck, you’ll know that there is little or no room for developing a new technology platform. Rather, it is about rescuing the top-line through Mega-Mergers with the few stilll growing large pharmaceutical companies, phase III, launch, and emerging markets, and managing the bottom-line by cutting in-house R&D. We’ve all heard it, again and again.

In essence, it is an acknowledgment that Big Pharma has failed as an innovation engine and R&D is no more a place to hide from responsibility in Big Pharma. The industry has decided that internal efforts that just serve as evaluation units of external technologies (e.g. delivery) without spearheading cutting-edge R&D themselves are not an efficient use of capital. Instead, if a therapeutic business unit was interested in a specific RNAi Therapeutics candidate, they can deal with the external company directly without the need for an in-house middleman. In fact, Pfizer has already pursued this alternative pathway as they have partnered the ddRNAi program for HCV with Tacere and a synthetic siRNA candidate from Quark for wet AMD. In both cases, there seemed to have been little involvement by Pfizer’s in-house oligonucleotide therapeutics unit.

This is not a criticism of the individuals themselves that have been part of those platform development units, but more one of an organizational nature. The more I learn about Big Pharma, the more I am struck by how little co-ordination there is within these sprawling organizations. For example, a group in one part of the world may utilize RNAi for target discovery and validation, but may not be fully aware of the technologies available from units elsewhere which work on the therapeutic aspects of RNAi.

It is, however, also a criticism of the arrogance of some organizations that innovation will happen if only you throw money at it. More than $500M by Roche, more than $200M by Pfizer, and more than $1.5B by Merck, and little to show in terms of delivery progress compared to a company like Tekmira with much more limited means. What is frustrating is that often money is spent on trying to replicate what already exists, such as LNP delivery, instead of admitting that innovation can’t be manufactured and if you really want to bring it in-house, then it is by buying it where it emerges, wherever in the world.

Almost on cue, the same day that Pfizer’s plans emerged, Marina Biotech announced a product-specific development deal with Swiss drug licensing and development company Debiopharm. This deal covers a pre-clinical stage RNAi Therapeutics program for bladder cancer (via topical LNP-siRNA administration) where much of the early development work will stay with Marina, but which will all be funded by Debiopharm, with potential downstream development milestones and royalties for Marina Biotech. Given the circumstances, severe cash crunch I would think, it is a good deal for Marina given the early stage of the program (pre-clinical). And who knows, maybe some of the work by Marina Biotech and Tekmira with Pfizer will similarly result in product-specific development deals with Pfizer therapeutic area units if results obtained thus far have been promising.

The Pfizer news is definitely not good for building investor confidence in RNAi Therapeutics, but long term it may just mean that companies with already viable clinical technologies will succeed as it will allow them to efficiently churn out and monetize high-quality development candidates, somewhat akin to what Quark’s and ISIS’ business models have been until now. That’s not to say that this is ideal for RNAi therapeutic technology development, but with maybe the exception of Alnylam, most companies won’t have many other choices.

Note: I am currently planning to resume more regular blogging as clinical results come in. Only these will be able to turn around sentiment for RNAi Therapeutics in a lasting manner.

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.